[8-K] Capricor Therapeutics Inc Reports Material Event

Rhea-AI Filing Summary

Capricor Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025; the press release is attached as Exhibit 99.1. The company states the release is being furnished, not filed, and therefore is not subject to Section 18 liability and will not be incorporated by reference into other Exchange Act filings unless expressly stated. The filing also includes a Cover Page Interactive Data File (inline XBRL) as Exhibit 104. The report identifies Capricor common stock trading as CAPR on The Nasdaq Capital Market and is signed by CEO Linda Marbán, Ph.D.. Investors should review Exhibit 99.1 for the detailed financial figures because the 8-K text here provides only the notice of the release.

Positive

• Press release furnished as Exhibit 99.1 announcing financial results for the quarter ended June 30, 2025.
• Cover Page Interactive Data File (inline XBRL) provided as Exhibit 104, enabling structured disclosure of cover-page data.

Negative

• No substantive financial figures or metrics are included in the 8-K text itself; investors must consult Exhibit 99.1 for the detailed results.
• The disclosure is furnished, not filed, which means it is not subject to Section 18 liability and will not be automatically incorporated by reference into other filings.

Insights

Securities Analyst

TL;DR Routine furnishing of Q2 results; limited immediate market impact without the press release text.

The 8-K notifies investors that Capricor has released its quarter-end financial results via a press release attached as Exhibit 99.1 and supplied inline XBRL as Exhibit 104. As the company expressly states the material is being furnished rather than filed, the disclosure does not carry Section 18 liabilities and is not automatically incorporated into other Exchange Act filings. On its face this is a procedural disclosure; the market impact depends on the actual figures and commentary contained in Exhibit 99.1.

Corporate Governance Expert

TL;DR Procedural 8-K: disclosure furnished and signed by the CEO; no new governance actions reported.

The filing documents that management provided a press release reporting quarterly financial results and included a signed cover page. There are no governance changes, officer departures, equity awards, or other corporate actions disclosed in the text of this report. The explicit statement that the release is furnished (not filed) limits the filing's role in creating additional SEC liabilities and in being incorporated by reference in later filings absent express language to the contrary.

0001133869false00011338692025-08-112025-08-11

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported)

​

August 11, 2025

​

CAPRICOR THERAPEUTICS, INC.

(Exact name of Registrant as Specified in its Charter)

​

	​		​
Delaware		001-34058		88-0363465
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(I.R.S. Employer Identification No.)

​

10865 Road to the Cure, Suite 150, San Diego, California
(Address of principal executive offices) 92121
(Zip Code)

​

(858) 727-1755

(Registrant’s telephone number, including area code)

​

Not Applicable

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		CAPR		The Nasdaq Capital Market

​

​

​

​

​

Item 2.02 Results of Operations and Financial Condition.

​

On August 11, 2025, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

​

The information under Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any of the Company’s filings under the Exchange Act, unless expressly set forth as being incorporated by reference into such filing.

​

Item 9.01Financial Statements and Exhibits.  

​

(d) Exhibits

​

99.1	​	Press Release, titled “Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update”, dated August 11, 2025.
​	​	​
104	​	Cover Page Interactive Data File (formatted as inline XBRL).

​

​

2

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

​

	CAPRICOR THERAPEUTICS, INC.
Date: August 11, 2025	By:	/s/ Linda Marbán, Ph.D.
		Linda Marbán, Ph.D.
		Chief Executive Officer

​

​

3

FAQ

What did Capricor (CAPR) disclose in this 8-K?

The company furnished a press release reporting its financial results for the quarter ended June 30, 2025, attached as Exhibit 99.1, and provided a Cover Page Interactive Data File (Exhibit 104).

Are the financial results included in the 8-K text?

No. The 8-K supplies notice that a press release was issued; the actual financial figures and commentary are in Exhibit 99.1 (the press release).

Was the press release filed with the SEC or furnished?

The press release was explicitly furnished, not filed, and therefore is not subject to Section 18 liability and is not incorporated by reference into other Exchange Act filings unless expressly stated.

Which securities exchange lists Capricor common stock and what is the ticker?

Capricor common stock trades on The Nasdaq Capital Market under the ticker CAPR.

Who signed the 8-K on behalf of Capricor?

The report is signed by Linda Marbán, Ph.D., Chief Executive Officer.